



## (51) International Patent Classification:

C12N 15/864 (2006.01) A61K 48/00 (2006.01)  
C07K 14/47 (2006.01) A61K 38/17 (2006.01)  
C07K 14/015 (2006.01) A61K 38/16 (2006.01)

## (21) International Application Number:

PCT/US2021/029253

## (22) International Filing Date:

26 April 2021 (26.04.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/016,246 27 April 2020 (27.04.2020) US  
63/088,432 06 October 2020 (06.10.2020) US

## (71) Applicant: 4D MOLECULAR THERAPEUTICS INC.

[US/US]; 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US).

## (72) Inventors: KOTTERMAN, Melissa; c/o 4D Molecular

Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). FRANCIS, Peter; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). CALTON, Melissa; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). GONZALES, Johnny; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). CROZE, Roxanne; c/o

4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). SCHMITT, Christopher; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US).

(74) Agent: CABRAL, Christopher, M. et al.; Much She-  
list PC, 191 N. Wacker Drive, Suite 1800, Chicago, IL  
60606-1615 (US).

## (81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## (54) Title: ADENO-ASSOCIATED VARIANTS, FORMULATIONS AND METHODS FOR PULMONARY DELIVERY




FIG. 1A

(57) Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

[Continued on next page]

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

**(88) Date of publication of the international search report:**

02 December 2021 (02.12.2021)